161 related articles for article (PubMed ID: 26786167)
21. [Pharmacotherapy of patients with (early) rheumatoid arthritis].
Jacobs JW; Blaauw AA; Dijkmans BA; van Riel PL; Bijlsma JW
Ned Tijdschr Geneeskd; 2000 Jan; 144(5):211-6. PubMed ID: 10682647
[TBL] [Abstract][Full Text] [Related]
22. [Combination therapy of disease-modifying antirheumatic drugs(DMARDs) in rheumatoid arthritis].
Kobayashi S; Kanai Y
Nihon Rinsho; 2002 Dec; 60(12):2351-6. PubMed ID: 12510361
[TBL] [Abstract][Full Text] [Related]
23. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
24. [Modern disease-modifying antirheumatic drugs].
Müller-Ladner U; Richter K; Tarner IH
Internist (Berl); 2015 Mar; 56(3):307-14. PubMed ID: 25700648
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy.
Smolen JS; Emery P; Kalden JR; Van Riel PL; Dougados M; Strand CV; Breedveld FC
J Rheumatol Suppl; 2004 Jun; 71():13-20. PubMed ID: 15170903
[TBL] [Abstract][Full Text] [Related]
26. The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.
Kavanaugh A; Smolen JS
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S19-21. PubMed ID: 24129131
[TBL] [Abstract][Full Text] [Related]
27. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
28. Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis.
Mullan RH; Bresnihan B
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S158-64. PubMed ID: 14969069
[TBL] [Abstract][Full Text] [Related]
29. Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis.
Pincus T; Yazici Y; Sokka T; Aletaha D; Smolen JS
Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S179-85. PubMed ID: 14969073
[TBL] [Abstract][Full Text] [Related]
30. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.
Cohen SB; Cohen MD; Cush JJ; Fleischmann RM; Mease PJ; Schiff MH; Simon LS; Weaver AL
J Rheumatol Suppl; 2008 Feb; 81():4-30; quiz 31-4. PubMed ID: 19193621
[TBL] [Abstract][Full Text] [Related]
31. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis.
Setoguchi S; Solomon DH; Weinblatt ME; Katz JN; Avorn J; Glynn RJ; Cook EF; Carney G; Schneeweiss S
Arthritis Rheum; 2006 Sep; 54(9):2757-64. PubMed ID: 16947774
[TBL] [Abstract][Full Text] [Related]
32. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
Ndongo S; Pouye A; Lekpa FK; Bihéhé DM; Tiendrebeogo J; Ndao AC; Ka MM; Moreira Diop T
Med Sante Trop; 2012; 22(4):385-9. PubMed ID: 23352953
[TBL] [Abstract][Full Text] [Related]
33. Safety overview of new disease-modifying antirheumatic drugs.
Cush JJ
Rheum Dis Clin North Am; 2004 May; 30(2):237-55, v. PubMed ID: 15172038
[TBL] [Abstract][Full Text] [Related]
34. Discontinuation of disease-modifying anti-rheumatic drugs and clinical outcomes in the Rheumatoid Arthritis DMARD Intervention and Utilisation Study 2 (RADIUS 2).
Gibofsky A; Cannon GW; Harrison DJ; Joseph GJ; Bitman B; Chaudhari S; Collier DH
Clin Exp Rheumatol; 2015; 33(3):297-301. PubMed ID: 25738333
[TBL] [Abstract][Full Text] [Related]
35. [Rheumatic ailments. Can arthritis drugs be tapered?].
Füessl HS; Stiefelhagen P
MMW Fortschr Med; 2015 Oct; 157(17):31. PubMed ID: 26759868
[No Abstract] [Full Text] [Related]
36. [Disease modifying anti-rheumatic drugs(DMARDs)].
Matsuda Y
Nihon Rinsho; 1999 Feb; 57(2):439-44. PubMed ID: 10078020
[TBL] [Abstract][Full Text] [Related]
37. Low-dose corticosteroids and disease modifying drugs in patients with rheumatoid arthritis.
Malysheva O; Baerwald CG
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S113-5. PubMed ID: 22018195
[TBL] [Abstract][Full Text] [Related]
38. [Influence of therapy on risk of cancer in rheumatoid arthritis. Pathophysiological principles].
Waldner MJ; Strangfeld A; Aringer M
Z Rheumatol; 2016 Feb; 75(1):13-21. PubMed ID: 26786169
[TBL] [Abstract][Full Text] [Related]
39. [Methotrexate].
Rau R
Z Rheumatol; 2016 Aug; 75(6):599-603. PubMed ID: 27365027
[No Abstract] [Full Text] [Related]
40. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
Nandi P; Kingsley GH; Scott DL
Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
